Eli Lilly, MiNA Therapeutics Launch Research Collaboration
07:52 AM EDT, 05/11/2021 (MT Newswires) -- Eli Lilly and Company (LLY) and MiNA Therapeutics, an RNA activation therapeutics company, said Tuesday they have launched a global research collaboration to develop novel drug candidates using MiNA's small activating RNA technology platform.
Under terms of the agreement, MiNA will utilize its saRNA platform to research up to five targets selected by Lilly that aim to address diseases across Lilly's key therapeutic focus areas.
Lilly will conduct the preclinical and clinical development of candidates and will retain exclusive commercialization rights for any products resulting from the collaboration.
MiNA will receive a $25 million upfront payment, along with potential development and commercialization milestones up to a total of $245 million per target, as well as tiered royalties from the low-single to low-double digits on product sales resulting from the partnership.
This partnership will be reflected in Lilly's GAAP-based financial results and financial guidance. There will be no change to its 2021 non-GAAP earnings per share guidance, the company said.
Price: 192.57, Change: -2.13, Percent Change: -1.09